NCT01989585 2026-03-19
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
3 trialsNCT04557956 2026-03-18
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT01902173 2025-01-14
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed